Formula sells BluePhoenix stake

Formula Systems, Herzliya-based information technology provider, announced over the weekend that it will sell all its holdings in technology firm BluePhoenix $64 million to international investors.

By YONI TEITZ
June 18, 2007 07:49

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

Formula Systems, Herzliya-based information technology provider, announced over the weekend that it will sell all its holdings in technology firm BluePhoenix $64 million to international investors. Formula is expected to realize a capital gain of about $18m. from the sale. BluePhoenix said that some or all of the Formula members of the BluePhoenix board are will resign following the sale. The sale was lead by C.E. Unterberg, Towbin, which is being acquired by Collins Stewart.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS